{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:08:05Z","timestamp":1792674485668,"version":"4.5.0"},"publisher-location":"New York, NY","reference-count":20,"publisher":"Springer New York","isbn-type":[{"value":"9781493986507","type":"print"},{"value":"9781493986514","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/978-1-4939-8651-4_4","type":"book-chapter","created":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T12:51:17Z","timestamp":1535719877000},"page":"69-76","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Nusinersen in the Treatment of Spinal Muscular Atrophy"],"prefix":"10.1007","author":[{"given":"Kara","family":"Goodkey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejal","family":"Aslesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,1]]},"reference":[{"issue":"3","key":"4_CR1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/ana.24864","volume":"81","author":"MA Farrar","year":"2017","unstructured":"Farrar MA, Park SB, Vucic S et al (2017) Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol 81(3):355\u2013368. https:\/\/doi.org\/10.1002\/ana.24864","journal-title":"Ann Neurol"},{"issue":"4","key":"4_CR2","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3390\/molecules22040563","volume":"22","author":"Valentina Sardone","year":"2017","unstructured":"Sardone V, Zhou H, Muntoni F et al (2017) Antisense oligonucleotide-based therapy for neuromuscular disease. Molecules 22(4). https:\/\/doi.org\/10.3390\/molecules22040563","journal-title":"Molecules"},{"issue":"4","key":"4_CR3","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","volume":"33","author":"SJ Kolb","year":"2015","unstructured":"Kolb SJ, Kissel JT (2015) Spinal muscular atrophy. Neurol Clin 33(4):831\u2013846. https:\/\/doi.org\/10.1016\/j.ncl.2015.07.004","journal-title":"Neurol Clin"},{"key":"4_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejhg.5200210","volume":"6","author":"JE Taylor","year":"1998","unstructured":"Taylor JE et al (1998) Correlation of SMNt and SMNc gene copy number with age of onset and survival in spinal muscular atrophy. Eur J Hum Genet 6:8. https:\/\/doi.org\/10.1038\/sj.ejhg.5200210","journal-title":"Eur J Hum Genet"},{"key":"4_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/tnsci-2017-0001","volume":"8","author":"EW Ottesen","year":"2017","unstructured":"Ottesen EW (2017) ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy. Transl Neurosci 8:1\u20136. https:\/\/doi.org\/10.1515\/tnsci-2017-0001","journal-title":"Transl Neurosci"},{"issue":"3","key":"4_CR6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/jpm3030144","volume":"3","author":"JJ Lee","year":"2013","unstructured":"Lee JJ, Yokota T (2013) Antisense therapy in neurology. J Pers Med 3(3):144\u2013176. https:\/\/doi.org\/10.3390\/jpm3030144","journal-title":"J Pers Med"},{"issue":"4","key":"4_CR7","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1128\/MCB.26.4.1333-1346.2006","volume":"26","author":"NK Singh","year":"2006","unstructured":"Singh NK, Singh NN, Androphy EJ et al (2006) Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol 26(4):1333\u20131346. https:\/\/doi.org\/10.1128\/MCB.26.4.1333-1346.2006","journal-title":"Mol Cell Biol"},{"key":"4_CR8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/gt.2017.79","volume":"24","author":"S Simoens","year":"2017","unstructured":"Simoens S, Huys I (2017) Market access of Spinraza (Nusinersen) for spinal muscular atrophy: intellectual property rights, pricing, value and coverage considerations. Gene Ther 24:539. https:\/\/doi.org\/10.1038\/gt.2017.79","journal-title":"Gene Ther"},{"issue":"10","key":"4_CR9","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","volume":"86","author":"CA Chiriboga","year":"2016","unstructured":"Chiriboga CA, Swoboda KJ, Darras BT et al (2016) Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology 86(10):890\u2013897. https:\/\/doi.org\/10.1212\/WNL.0000000000002445","journal-title":"Neurology"},{"issue":"6","key":"4_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1358\/dot.2017.53.6.2652413","volume":"53","author":"DM Paton","year":"2017","unstructured":"Paton DM (2017) Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy. Drugs Today (Barc) 53(6):327\u2013337. https:\/\/doi.org\/10.1358\/dot.2017.53.6.2652413","journal-title":"Drugs Today (Barc)"},{"issue":"6","key":"4_CR11","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1517\/14712598.2014.896335","volume":"14","author":"A Touznik","year":"2014","unstructured":"Touznik A, Lee JJ, Yokota T (2014) New developments in exon skipping and splice modulation therapies for neuromuscular diseases. Expert Opin Biol Ther 14(6):809\u2013819. https:\/\/doi.org\/10.1517\/14712598.2014.896335","journal-title":"Expert Opin Biol Ther"},{"key":"4_CR12","unstructured":"Disterer P (2017) This is the dawning of the age of antisense. Oligonucleotide Therapeutics Society. Accessed 23 Jan 2018"},{"issue":"4","key":"4_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1128\/MCB.26.4.1333-1346.2006","volume":"26","author":"NK Singh","year":"2006","unstructured":"Singh NK, Singh NN, Androphy EJ, Singh RN (2006) Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol 26(4):13. https:\/\/doi.org\/10.1128\/MCB.26.4.1333-1346.2006","journal-title":"Mol Cell Biol"},{"issue":"4","key":"4_CR14","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","volume":"77","author":"SM Hoy","year":"2017","unstructured":"Hoy SM (2017) Nusinersen: first global approval. Drugs 77(4):473\u2013479. https:\/\/doi.org\/10.1007\/s40265-017-0711-7","journal-title":"Drugs"},{"issue":"1","key":"4_CR15","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1038\/s41598-017-03850-2","volume":"7","author":"A Touznik","year":"2017","unstructured":"Touznik A, Maruyama R, Hosoki K et al (2017) LNA\/DNA mixmer-based antisense oligonucleotides correct alternative splicing of the SMN2 gene and restore SMN protein expression in type 1 SMA fibroblasts. Sci Rep 7(1):3672. https:\/\/doi.org\/10.1038\/s41598-017-03850-2","journal-title":"Sci Rep"},{"key":"4_CR16","unstructured":"Bob Pratt PD (2016) Risk assessment and risk mitigation review(s) FDA, Division of Risk Management (DRISK)"},{"issue":"39","key":"4_CR17","doi-asserted-by":"publisher","first-page":"10962","DOI":"10.1073\/pnas.1605731113","volume":"113","author":"SM Hammond","year":"2016","unstructured":"Hammond SM, Hazell G, Shabanpoor F et al (2016) Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. Proc Natl Acad Sci U S A 113(39):10962\u201310967. https:\/\/doi.org\/10.1073\/pnas.1605731113","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16","key":"4_CR18","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1073\/pnas.1613203114","volume":"114","author":"Y Echigoya","year":"2017","unstructured":"Echigoya Y, Nakamura A, Nagata T et al (2017) Effects of systemic multi-exon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 114(16):4213\u20134218","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4_CR19","doi-asserted-by":"crossref","unstructured":"Maruyama R, Echigoya Y, Nakamura A et al (2017) Systemic injections of peptide-conjugated morpholinos improve cardiac symptoms of a dog model of duchenne muscular dystrophy. Paper presented at the molecular therapy","DOI":"10.1073\/pnas.1613203114"},{"issue":"18","key":"4_CR20","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1093\/hmg\/ddu198","volume":"23","author":"EY Osman","year":"2014","unstructured":"Osman EY, Miller MR, Robbins KL et al (2014) Morpholino antisense oligonucleotides targeting intronic repressor Element1 improve phenotype in SMA mouse models. Hum Mol Genet 23(18):4832\u20134845. https:\/\/doi.org\/10.1093\/hmg\/ddu198","journal-title":"Hum Mol Genet"}],"container-title":["Methods in Molecular Biology","Exon Skipping and Inclusion Therapies"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-8651-4_4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T05:45:15Z","timestamp":1571809515000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-8651-4_4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9781493986507","9781493986514"],"references-count":20,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-8651-4_4","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}